38.56 0.00 (0.00%)
After hours: 6:24PM EST
|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||38.27 - 38.56|
|52 Week Range||34.52 - 44.54|
|PE Ratio (TTM)||29.44|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||2.01 (5.27%)|
|1y Target Est||42.72|
Johnson & Johnson’s (JNJ) Consumer segment includes oral care products, beauty products, baby care products, over-the-counter products, women’s health products, and wound care products. Johnson & Johnson’s beauty franchise is expected to report growth in revenues in 4Q17 due to the strong performance of products acquired from Vogue International and some new products.
When investors think of dividend stocks, pharmaceutical and biotech companies aren’t usually front of mind. Even though drugs are relatively non-cyclical, these stocks are subjected to high regulatory risks. Yet,Read More...
Promising data from several pivotal studies and a rapid pipeline progress contribute to a rally in Johnson & Johnson's (JNJ) shares.
Shares of Neurometrix Inc (NASDAQ:NURO) rocketed more than 60% higher at one point Wednesday morning after the healthcare company announced a new collaboration with GlaxoSmithKline plc (ADR) (NYSE:GSK), involving Quell, the company's over-the-counter, 100% drug free chronic pain relief wearable. Specifically, GSK Consumer Healthcare acquires exclusive ownership of Quell technology for markets outside the U.S. Neurometrix will receive a payment of $5 million for the assets relating to Quell technology for markets outside the U.S and up to $21.5 million, upon the achievement of certain development and commercialization milestones. Investors will need to wait to see more precise details, but for a penny stock such as Neurometrix, this is pretty amazing no matter the exact dollar amount.
GlaxoSmithKline (GSK.L) is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent. The move, which a GSK spokesman said on Wednesday would result in an unspecified number of job losses in sub-Saharan Africa, follows disappointing sales for many pharmaceutical companies in the region. Five years ago, forecasters predicted annual African drug sales would reach $45 billion by 2020.
GlaxoSmithKline is cutting back operations in Africa as its new Chief Executive Emma Walmsley seeks to make the British drugmaker more competitive in emerging markets by ditching her predecessor's expansion plans for the continent. The move, which a GSK spokesman said on Wednesday would result in an unspecified number of job losses in sub-Saharan Africa, follows disappointing sales for many pharmaceutical companies in the region.
Shares of NeuroMetrix Inc. rocketed 78% toward a 7-month high in active premarket trade Wednesday, after chronic pain treatments company announced a collaboration with GlaxoSmithLine PLC involving NeuroMetrix's ...
GlaxoSmithKline Plc is cutting jobs in Africa and restructuring in more than two dozen countries across the continent, reversing earlier expansion efforts as new Chief Executive Emma Walmsley tries to ...
WALTHAM, Mass., Jan. 17, 2018-- NeuroMetrix, Inc. announced today a collaboration with GlaxoSmithKline, one of the world's largest science-led global healthcare companies, involving Quell ® Wearable Pain ...
Investors seeking to preserve capital in a volatile environment might consider large-cap stocks such as GlaxoSmithKline plc (LSE:GSK) a safer option. Market participants who are conscious of risk tend toRead More...
Insys (INSY) is taking strategic steps to restore stakeholder confidence. The company aims to achieve one NDA (or new drug application) per year over the next five years. Insys is targeting treatments for orphan diseases, neurological diseases like pediatric epilepsy, genetic conditions like Prader-Willi syndrome, and treatments for secondary allergic reactions, anorexia, and products for opioid overdose.
Thus, interaction with government agencies occurs regularly. Insys (INSY) has been a part of several government investigations recently. Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.
Insys’s (INSY) net revenues decreased from $57.7 million in 3Q16 to $30.7 million in 3Q17, which was attributable to a decrease in Subsys sales. As a result, the gross profit of the company decreased to $23.1 million in 3Q17 as compared with $53 million for 3Q16. The general and administrative expenses of the company decreased to $15.7 million in 3Q17 as compared with $17.7 million for 3Q16.
PHILADELPHIA , Jan. 12, 2018 /PRNewswire/ -- GSK announced today it has received approval from the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research expanding ...
Focus this week was on pipeline updates provided by several companies including Pfizer (PFE) at a healthcare conference while Novo Nordisk's bid to acquire Ablynx also made news.
AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.
Teva Pharmaceuticals released its 3Q17 earnings results on November 2, 2017. The disappointing earnings and the company’s lowering of its fiscal 2017 guidance triggered negative investor sentiments, which led to a massive decline of approximately 20% in TEVA stock prices. The company has run into troubles over the past year and it reported a dismal performance in 3Q17. For details, read, Inside Teva’s 3Q17 Performance.
Novartis (NVS) announced the initiation of a trial on the biosimilar version of Cosentyx which will compare the drug to its proposed biosimilar for the treatment of ankylosing spondylitis.